Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer

Erin M McClure; Geoffrey Sedor; Mairead Moloney; Yuxuan Jin; Lio Yu; Michael W Kattan

doi:10.1016/j.adro.2024.101463

Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin Cancer

Adv Radiat Oncol. 2024 Feb 9;9(12):101463. doi: 10.1016/j.adro.2024.101463. eCollection 2024 Dec.

Authors

Erin M McClure¹, Geoffrey Sedor², Mairead Moloney³, Yuxuan Jin⁴, Lio Yu⁵, Michael W Kattan⁴

Affiliations

¹ University Hospitals Geauga Medical Center, Chardon, OH.
² Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, New York.
³ New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
⁴ Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
⁵ Laserderm Dermatology, Smithtown, New York.

Abstract

Purpose: This is the first study to quantify the 2-year freedom from recurrence for individuals with nonmelanoma skin cancer (NMSC) such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and squamous carcinoma in situ (SCCIS) treated with image guided superficial radiation therapy (IGSRT) versus SRT without image guidance.

Methods and materials: This retrospective cohort study evaluates the 2-year freedom recurrence rate of NMSCs treated by IGSRT (March 2016 to January 2022) and compares it to existing data on NMSCs treated by SRT via 1 sample proportion tests. Individuals >18 years old with biopsy-proven SCC, SCCIS, and/or BCC treated with IGSRT were included in the study, and 1602 patients/2880 treated lesions were followed until January 14, 2022. SRT literature was identified through an Ovid Medline search.

Results: All NMSCs treated by IGSRT in this cohort had an aggregate 2-year freedom from recurrence of 99.23%. The recurrence rate for BCC (N = 1382) was 1.1%, for SCC (N = 904) 0.8%, and for SCCIS (N = 594) 0.0%. These recurrence rates are significantly improved compared with a pooled study that evaluated NMSCs across histology and BCCs alone treated without image guidance (standard SRT) (P < .001).

Conclusions: IGSRT offers a paradigm-shifting treatment option for patients with NMSCs - offering statistically significantly improved outcomes compared with standard SRT and a more desirable toxicity profile to surgical options. This study demonstrates that IGSRT is associated with remarkably low recurrence rates, which are statistically significantly improved from the previous generation of SRT and in line with modern outcomes for Mohs micrographic surgery.